Evidence map›Paper›PMID 32357518›Full record

ArticleCancers2020

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.

Martin Michaelis, Mark N Wass, Ian Reddin, Yvonne Voges, Florian Rothweiler, Stephanie Hehlgans, Jaroslav Cinatl, Marco Mernberger, Andrea Nist, Thorsten Stiewe and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Martin MichaelisIndustrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Mark N WassIndustrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Ian ReddinIndustrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.
Yvonne VogesInstitute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596 Frankfurt, Germany.
Florian RothweilerInstitute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596 Frankfurt, Germany.
Stephanie HehlgansDepartment of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt am Main, 60590 Frankfurt, Germany.
Jaroslav CinatlInstitute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596 Frankfurt, Germany.
Marco MernbergerInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps-University, 35032 Marburg, Germany.
Andrea NistGenomics Core Facility, Philipps-University, 35043 Marburg, Germany.
Thorsten StieweInstitute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps-University, 35032 Marburg, Germany.
Franz RödelDepartment of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt am Main, 60590 Frankfurt, Germany.
Jindrich CinatlInstitute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596 Frankfurt, Germany.
Goethe University Frankfurt · DEUniversity of Kent · GBPhilipps University of Marburg · DEGerman Center for Lung Research · DE

Funding

Frankfurter Stiftung für krebskranke Kinder n/aHilfe für krebskranke Kinder Frankfurt e.V. n/a
6 · The paper itself

Abstract

Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased SLC35F2 (mediates YM155 uptake) levels, decreased survivin levels, and

Indexed as

acquired drug resistancebiomarkersBIRC5intrinsic drug resistanceneuroblastomasurvivintherapy monitoring

Identifiers

PMID32357518
PMCPMC7281096
OpenAlexW3018748254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.